Mesenchymal Stem Cell Therapy for Bipolar Disorder Immune Modulation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for bipolar disorder are inconsistent and fail to address its underlying causes, leading to misdiagnosis and delayed correct diagnosis, particularly as it often presents with symptoms similar to major depressive disorder.

Innovation Solution

Administration of regenerative cell populations, including mesenchymal stem cells and modified stem cells, which are selected based on specific markers and treated with carbon monoxide to stimulate expression of HIF-1 alpha and heme oxygenase, to target augmented Th17, Th9, and Th1 cells, and their associated cytokines, thereby addressing the underlying immune dysregulation in bipolar disorder.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for bipolar disorder, then symptom management is achieved, but underlying causes are not addressed and diagnosis is delayed

Engineering Contradiction:

Improvediagnostic accuracyVSAvoiddiagnosis delay

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent introduces mesenchymal stem cells as an intermediary substance that mediates between the patient's immune system and the disease process. These cells are administered to modulate the immune response and address underlying causes of bipolar disorder, thereby improving diagnostic accuracy and reducing diagnosis delay by providing a biological marker-based approach that can distinguish bipolar disorder from major depressive disorder.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent utilizes changes in cytokine levels and immune cell parameters as diagnostic and therapeutic targets. By measuring and modulating specific cytokines and immune cell populations, the patent enables more accurate diagnosis and treatment of bipolar disorder, resolving the contradiction between reliable diagnosis and time loss.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If mesenchymal stem cells are administered to treat bipolar disorder, then immune dysregulation is addressed, but cell selection and modification processes become complex

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidcell processing complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by selectively modifying specific properties of mesenchymal stem cells based on their intended function. Different cell populations are selected and modified according to their specific therapeutic roles, such as enhancing anti-inflammatory properties for certain indications while maintaining other properties for different applications, thereby achieving reliable therapeutic effectiveness without requiring complete complexity of cell processing.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent segments the cell processing into distinct stages: cell selection based on markers, conditional modification based on specific disease characteristics, and administration. This segmentation allows for manageable complexity while maintaining therapeutic effectiveness by addressing only the necessary cell properties for each patient's specific condition.

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of regenerative cells reduces bipolar behavior and cytokine levels, providing a therapeutic effect by modulating the immune response and potentially improving symptoms of bipolar disorder.

Implementation Method 1

treated with carbon monoxide to stimulate expression of HIF-1 alpha and heme oxygenase

Methodology Applied

Scientific EffectHIF-1 alpha expression induction:

Implementation Method 2

treated with carbon monoxide to stimulate expression of HIF-1 alpha and heme oxygenase

Methodology Applied

Scientific EffectHeme oxygenase expression induction:

Implementation Method 3

target augmented Th17, Th9, and Th1 cells, and their associated cytokines, thereby addressing the underlying immune dysregulation in bipolar disorder

Methodology Applied

Scientific EffectImmune cell modulation:

Implementation Method 4

reduces bipolar behavior and cytokine levels, providing a therapeutic effect by modulating the immune response

Methodology Applied

Scientific EffectCytokine reduction:

Data Source

PatentUS20240091269A1Treatment of bipolar disorder using mesenchymal stem cells and modification of mesenchymal stem cells

Publication Date: 2024.03.21 THERAPEUTIC SOLUTIONS INTERNATIONAL INC

AI summary

The invention discloses the utilization of mesenchymal stem cells, exosomes from mesenchymal stem cells, conditioned media from mesenchymal stem cells, apoptotic bodies from mesenchymal stem cells, and modified mesenchymal stem cells for treatment of bipolar disorder. In one embodiment mesenchymal stem cells isolated from umbilical cord tissue are treated carbon monoxide at a concentration sufficient to induce activation of heme-oxygenase I and infused into a patient at risk or suffering from bipolar disorder.